BLUE News 19.90 Bluebird Bio Inc (BLUE)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 17, 2014 at 7:52 PM

Bluebird Bio Inc (BLUE) 19.90 $BLUE

Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday

What Falling Estimates & Price Mean for bluebird bio (BLUE) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:43AM CDT
One such stock that you may want to consider dropping is bluebird bio which witnessed negative earnings estimate revisions in current quarter and current year.

Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday

bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia
Business Wire - Thu Mar 27, 6:00AM CDT
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio's LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.

Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

'Mad Money' Lightning Round: VMware Is the One to Own
at The Street - Fri Mar 21, 5:00AM CDT
Cramer wants you to buy more Celgene at $140 and thinks Bluebird Bio is going higher.

Jim Cramer's 'Mad Money' Recap: Did You Panic Wednesday? Too Bad
at The Street - Thu Mar 20, 7:25PM CDT
You missed out on substantial gains, particularly in financials and technology, Cramer says.

bluebird bio Reports Fiscal Year End 2013 Financial Results
Business Wire - Wed Mar 05, 3:30PM CST
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013. At fiscal year end bluebird bio held $206.3 million in cash and cash equivalents.

New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.

bluebird bio to Present at the Cowen and Company Health Care Conference
Business Wire - Wed Feb 26, 5:00PM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Cowen and Company 34th Annual Health Care Conference to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel, Boston, MA. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Tuesday, March 4, 2014 at 8:00 AM (ET).

bluebird bio to Present at the Leerink Global Healthcare Conference
Business Wire - Wed Feb 05, 3:15PM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Leerink Global Healthcare Conference to be held February 12 - 13, 2014 at the Waldorf Astoria Hotel, New York, NY. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Wednesday, February 12, 2014 at 8:25 AM (ET).

The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron
at The Street - Thu Jan 23, 7:00AM CST
Sangamo benefits from a Biogen partnership, but what does it mean for rivals Bluebird and Acceleron?

2 Biotech Stocks Spiking on Unusual Volume
at The Street - Thu Jan 16, 6:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.

J.P. Morgan Healthcare Confab Live Blog: Day Three
at The Street - Wed Jan 15, 9:12AM CST
TheStreet's Adam Feuerstein is providing live coverage of the most important healthcare investor conference of the year.

Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

bluebird bio Appoints Dr James Mandell to its Board of Directors
Business Wire - Thu Jan 09, 5:29AM CST
bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell, M.D. has joined the company's board of directors. In addition, bluebird bio announced that Axel Polack, Ph.D., general partner at TVM Capital Partners, has stepped down from the board.

bluebird bio to Present at the J.P.Morgan Healthcare Conference
Business Wire - Wed Jan 08, 5:59AM CST
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the 32nd Annual J.P.Morgan Healthcare Conference to be held January 13 - 16, 2014 at the Westin St Francis Hotel, San Francisco, CA. Nick Leschly, Chief bluebird, will provide an overview of the company at the conference on Wednesday, January 15, 2014 at 10:30 AM (PT).

22 Biotech Stock Predictions for 2014
at The Street - Mon Jan 06, 6:58AM CST
TheStreet's Adam Feuerstein offers his biotech stock outlook for 2014 and grades his 2013 predictions.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...